WSC 2022
Lys Therapeutics announces to attend the 14th World Stroke Organization Congress (#WSC2022, 26-29 October 2022) in person in #Singapore.
Lys Therapeutics and Institut BB@C – Blood and Brain @ Caen normandie are proud to be presenting during this conference new groundbreaking preclinical data using Lys Therapeutics’s lead candidate in ischemic #stroke.
Dr. Manuel BLANC, CEO, is happy to meet you there.
đź’Ş All together against Stroke and its dramatic consequences.
— https://lnkd.in/dUyuWkp6 —
———-
#WSC2022 #WSO #Stroke #neurosciences #clinicaltrials #Research #PublicPrivatePartnership #Collaboration #deeptech #biotech #healthcare #lifesciences #CNS #NeurologicalDiseases #NeurovascularDisorders #stroke #dementia #innovation #MedicalNeeds #LysTherapeutics #Glunomab #Glunozumab
With the World Stroke Organization, ETAP-Lab – Preclinical CRO , CHU de Caen Normandie, Inserm and Inserm Transfert, UniversitĂ© de Caen Normandie, CYCERON, ADNormandie, LyonbiopĂ´le and Bpifrance.
